SLC5A2 and heart failure: The first observations of the benefits of SGLT-2 inhibitors on Heart Failure were noted in the EMPA-REG (2015), CANVAS trial (2017), and Declare-TIMI 58 (2018) cardiovascular outcomes trials (CVOTs) [23,24].